Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERI-0036
- Development stage
- Preclinical
- Lead developer
- Novatium Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
ERI-0036 is a universal (allogeneic) Chimeric Antigen Receptor (CAR) T-cell therapy being developed by Novatium in partnership with Factor Bioscience. It is designed to treat renal cell carcinoma by targeting the CD5 and CD52 antigens. As an allogeneic, "off-the-shelf" therapy, ERI-0036 is engineered from healthy donor cells rather than the patient's own cells, likely utilizing Factor Bioscience's mRNA-based cell reprogramming and gene-editing technologies to prevent graft-versus-host disease and host-mediated rejection. The therapy aims to provide a standardized, readily available treatment option for patients with solid tumors expressing these targets. It is currently in the discovery-to-preclinical phase of development.
- Other names
- Novatium CD5-CD52-Universal CAR-TERI-0036-Novatium-CD5-CD52-Universal (allogeneic) CAR-T cell therapy-Renal cell carcinoma
02
Targets
CD52 (CD52 Antigen)CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on ERI-0036.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERI-0036.